Navigation Links
JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- JLL Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, "JLL"), announced today that as at 6:00 p.m. (Toronto time) on June 1, 2009 (the "Expiry Time") a total of 33,667,752 Restricted Voting Shares in the capital of Patheon Inc. ("Patheon") have been validly deposited to JLL's offer to acquire, at a price of US$2.00 cash per Restricted Voting Share, all of the issued and outstanding Restricted Voting Shares of Patheon (the "Offer"). As all of the conditions of the Offer have been met, JLL has taken up and made payment to the Depository for all of the Restricted Voting Shares validly deposited as of the Expiry Time. Payment will be made on or before Thursday, June 4, 2009 to Patheon shareholders who have validly deposited their Restricted Voting Shares under the Offer since May 19, 2009.

The Restricted Voting Shares taken up since the Offer was launched represent approximately 38% of the outstanding Restricted Voting Shares of Patheon not already owned by JLL or its affiliates and associates. Together with the Restricted Voting Shares owned prior to the Offer, JLL or its affiliates and associates now own 35,317,752 Restricted Voting Shares of Patheon or approximately 39% of the outstanding Restricted Voting Shares of Patheon. JLL also holds 150,000 convertible preferred shares convertible into Restricted Voting Shares representing approximately 29% of the currently issued and outstanding Restricted Voting Shares on an as-converted basis. If JLL were to convert its convertible preferred shares, which it is free to do at any time, it would hold in the aggregate 57% of the total number of Restricted Voting Shares issued and outstanding and would be entitled to vote such securities at any shareholders meeting. JLL will continue to assess whether or not to convert its convertible preferred shares as facts and circumstances develop.

JLL also announced that it has extended the Offer which will now expire ten days from the mailing of a formal notice of extension. JLL expects to mail a formal notice of extension to Patheon shareholders shortly. JLL intends to take up and pay for any further Restricted Voting Shares as and when they are deposited.

About JLL Partners

JLL Partners, Inc. is a New York-based leading private equity investment firm with approximately $4.0 billion of capital under management. JLL's investment philosophy is to partner with outstanding management teams and invest with them in companies that they can continue to grow into market leaders. JLL has invested in a variety of industries, with special focus on financial services, building products, and healthcare services and medical products. More information on JLL can be found on the website www.jllpartners.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements that involve risks and uncertainties. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "expected", "scheduled", "estimates", "intends", "anticipates", or "believes", or variations of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. These forward-looking statements reflect JLL's best judgment based on current information, factors and assumptions, and although it bases these statements on circumstances that it believes to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance or actions, and actual performance and actions may vary materially from the actions and expectations discussed in this documentation. JLL disclaims any intention or obligation to update or revise any forward looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

    The Information Agent for the          The Dealer Manager for the
     Offer is:                              Offer is:

    Laurel Hill Advisory Group             UBS Securities Canada Inc.
    366 Bay Street, Suite 200              161 Bay Street
    Toronto, ON  M5H 4B2                   Suite 4100, P.O. Box 617
    Telephone Toll Free (North             Toronto, ON  M5J 2S1
     America):(888) 290-1555               Telephone: (416) 350-2201
    Telephone Collect (outside North
     America): (416) 637-4661


'/>"/>
SOURCE JLL Partners
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Resource for Those Living with Hepatitis C Announces Website Redesign
2. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
3. Immucor Announces Fiscal Year 2010 Guidance
4. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
5. ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
6. Michael J. Fox Foundation Announces Launch of PD Online Research
7. Roshan Announces Expansion of Afghanistans First Telemedicine Project to Bamyan Region
8. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
9. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
10. Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic
11. MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: